Work

Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial.

Year: 2010

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2010.28.15_suppl.4509

Authors: H. I. Scher, K. N. Chi, R. De Wit, W. R. Berry, P. Albers, B. Henick, P. Venner, A. Heidenreich, L. Chu, G. Heller

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2591560728

Cites:

Cited by: 26

Related to: 10